Publications
Publication
Inhibition of C1q, Initiator of the Classical Complement Cascade, by ANX005 for the Treatment of Guillain-Barré Syndrome: Results from a Phase 1b Study (.pdf download for full audio )
2020 American Academy of Neurology (AAN) Annual Meeting
May 2020
Publication
On Complement, Memory, and Microglia
The New England Journal of Medicine
May 2020
Neurodegeneration
Microglia mediate forgetting via complement-dependent synaptic elimination
Science
February 2020
Neurodegeneration
NFL is a marker of treatment response in children with SMA treated with nusinersen
Journal of Neurology
May 2019
Autoimmune Disease
Efficient design and analysis of randomized controlled trials in rare neurological diseases: An example in Guillain-Barré syndrome
PLOS ONE
February 2019
MOA
Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases
International Journal of Toxicology
December 2017
Neurodegeneration
‘Beyond amyloid’: A look at what’s next in Alzheimer’s research?
STAT
August 2017
Neurodegeneration
Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation
Cell
September 2016
Neurodegeneration
This woman may know a secret to saving the brain’s synapses
Science
August 2016
Neurodegeneration
Microglia: Phagocytosing to Clear, Sculpt, and Eliminate
Cell Development
July 2016
Neurodegeneration
Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma
Molecular Neurodegeneration
April 2016
Neurodegeneration
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Science
April 2016
MOA
Complement mediates pathological pruning
Nature Reviews
April 2016
Autoimmune Disease
C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy
Acta Neuropathologica Communications (2016) 4:23 DOI 10.1186/s40478-016-0291-x
March 2016
Neurodegeneration
C1q propagates microglial activation and neurodegeneration in the visual axis following retinal ischemia/reperfusion injury
Molecular Neurodegeneration
March 2016
Neurodegeneration
C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy
Acta Neuropathologica Communications
March 2016
Neurodegeneration
Schizophrenia risk from complex variation of complement component 4
Nature
February 2016
MOA
Complement, a target for therapy in inflammatory and degenerative diseases
Nature Reviews Drug Discovery
October 2015
Neurodegeneration
Rise of the Microglia: New research shows that the resident immune cells of the brain are involved in both development and disease
Scientific American
October 2015
Neurodegeneration
A Dramatic Increase of C1q Protein in the CNS during Normal Aging
J of Neuroscience
August 2013
Autoimmune Disease
C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica
Acta Neuropathologica
June 2013
MOA
The New View of Complement
Science
August 2012
Neurodegeneration
The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease
Annual Review of Neuroscience
July 2012
Neurodegeneration
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Neuron
May 2012
Neurodegeneration
Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma
J Clinical Investigation
April 2011
Neurodegeneration
The Role of the Classical Complement Cascade in Synapse Loss During Development and Glaucoma
Advances in Experimental Medicine and Biology
July 2010
Neurodegeneration
The Classical Complement Cascade Mediates CNS Synapse Elimination
Cell
December 2007
Posters
Autoimmune Disease
ANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation Triggered By Cold Agglutinins in Human Disease
Blood
September 2016
Neurodegeneration
Characterization of a function blocking anti-C1q antibody and its evaluation in neurodegenerative disease models.
2016 Keystone Conference
September 2016
Neurodegeneration
ANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation Triggered By Cold Agglutinins in Human Disease
2016 ASH Annual Meeting
September 2016
Neurodegeneration
Characterization and development of ANX005, a novel function blocking anti-C1q antibody for treatment of autoimmune and neurodegenerative disease
2017 AAN Annual Meeting
September 2017